Aberrant expression of β-catenin in CD4+ T cells isolated from primary progressive multiple sclerosis patients

[1]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[2]  S. Manicassamy,et al.  Modulation of Inflammatory Responses by Wnt/β-Catenin Signaling in Dendritic Cells: A Novel Immunotherapy Target for Autoimmunity and Cancer , 2016, Front. Immunol..

[3]  P. Sørensen,et al.  The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects , 2016, Therapeutic advances in neurological disorders.

[4]  E. Mazzon,et al.  Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action? , 2015, Current molecular medicine.

[5]  G Giovannoni,et al.  The evidence for a role of B cells in multiple sclerosis , 2012, Neurology.

[6]  K. Hawker,et al.  Progressive multiple sclerosis: characteristics and management. , 2011, Neurologic clinics.

[7]  E. Arenas,et al.  Emerging roles of Wnts in the adult nervous system , 2010, Nature Reviews Neuroscience.

[8]  S. Galande,et al.  Global Regulator SATB1 Recruits β-Catenin and Regulates TH2 Differentiation in Wnt-Dependent Manner , 2010, PLoS biology.

[9]  M. Mandal,et al.  β-Catenin/Tcf Determines the Outcome of Thymic Selection in Response to αβTCR Signaling1 , 2009, The Journal of Immunology.

[10]  D. Rowitch,et al.  Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. , 2009, Genes & development.

[11]  J. Lafaille,et al.  Swift Entry of Myelin-Specific T Lymphocytes into the Central Nervous System in Spontaneous Autoimmune Encephalomyelitis1 , 2008, The Journal of Immunology.